Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$776.38 USD

776.38
8,254,426

-29.68 (-3.68%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $774.63 -1.75 (-0.23%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (59 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks News

Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know

Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?

Smart Beta ETF report for RSPH

Should You Invest in the Vanguard Health Care ETF (VHT)?

Sector ETF report for VHT

Alector (ALEC) Up 7% on Finishing Enrolment in Alzheimer Study

Alector (ALEC) completes enrolment in a mid-stage study evaluating its investigational monoclonal antibody in patients with early Alzheimer's disease. Data from the study is expected before year-end.

Zacks Investment Ideas feature highlights: IonQ, E.L.F Beauty, Amazon, Meta Platforms and Eli Lilly

IonQ, E.L.F Beauty, Amazon, Meta Platforms and Eli Lilly are part of the Zacks Investment Ideas article.

Here's How Much You'd Have If You Invested $1000 in Eli Lilly a Decade Ago

Holding on to popular or trending stocks for the long-term can make your portfolio a winner.

Andrew Rocco headshot

4 Expert Tips for Navigating a Gap Down Market

Investors must learn to thrive in turbulent times. Stock Strategist Andrew Rocco provides 4 ways to hadle "tape bombs"

Prothena (PRTA) Skyrockets 88.7% in 12 Months: Here's Why

Prothena (PRTA) gains a massive 88.7% in 12 months on pipeline progress with its AD candidates.

Why Is Lilly (LLY) Up 6.4% Since Last Earnings Report?

Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Novo Nordisk (NVO) Launches Wegovy in UK Amid Supply Issues

Novo Nordisk (NVO) announces the controlled and limited launch of Wegovy in the U.K. amid rising demand for weight loss treatment and supply constraints.

Should Invesco S&P 100 Equal Weight ETF (EQWL) Be on Your Investing Radar?

Style Box ETF report for EQWL

Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.

Medicare's First Price Negotiation List Targets Expensive Drugs (Revised)

The negotiations with participating drug companies are likely to happen in 2023 and 2024 with the negotiated prices, if any, going into effect in 2026.

Kinjel Shah headshot

Medicare's First Price Negotiation List Targets Expensive Drugs

The negotiations with participating drug companies are likely to happen in 2023 and 2024 with the negotiated prices, if any, going into effect in 2026.

Novo Nordisk's (NVO) Shares Jump 17% in a Month: Here's Why

Novo Nordisk's (NVO) commercial and pipeline progress with its popular obesity drug, Wegovy, continues to drive the share price momentum.

If You Invested $1000 in Eli Lilly a Decade Ago, This is How Much It'd Be Worth Now

Holding on to popular or trending stocks for the long-term can make your portfolio a winner.

Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?

Style Box ETF report for FTCS

The Zacks Analyst Blog Highlights Eli Lilly, UnitedHealth, Walmart, Applied Materials and BCE

Eli Lilly, UnitedHealth, Walmart, Applied Materials and BCE are included in this Analyst Blog.

Sheraz Mian headshot

Top Research Reports for Eli Lilly, UnitedHealth & Walmart

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), UnitedHealth Group Incorporated (UNH) and Walmart Inc. (WMT).

Zacks Industry Outlook Highlights Eli Lilly, J&J, Novo Nordisk, Novartis and AstraZeneca

Eli Lilly, J&J, Novo Nordisk, Novartis and AstraZeneca are part of the Zacks Industry Outlook article

Derek Lewis headshot

These 3 Large-Cap Pharma Stocks Have Been Red-Hot

Large-cap pharmaceuticals have enjoyed buying pressure over the last month, delivering outsized gains to investors. And these three stocks have helped lead the charge.

Kinjel Shah headshot

5 Large Drug Stocks to Watch as New Drug Approvals & M&A Gain Pace

Drug, biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), Novo Nordisk (NVO), Novartis (NVS) and AstraZeneca (AZN) are worth retaining in your portfolio.

Amphastar Pharma (AMPH) Stock Skyrockets 89% YTD: Here's Why

Amphastar Pharma (AMPH) shares are up 89.1% year to date due to the acquisition of Baqsimi from Lilly. The company also receives FDA approval for Naloxone.